Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-1431 in Adult Tourette Syndrome or Chronic Motor Tic Disorder
2018-000100-41Phase 2Completed
- Sponsor
- Abide Therapeutics
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tourette syndrome (TS) and motor tic disorder comparing ABX-1431 with Placebo (2 arms). Primary endpoint: Change from baseline in YGTSS Total Tic Score. Started Aug 2018; status: completed.
02
Drugs
ABX-1431
03
Conditions
Tourette syndrome (TS)motor tic disorder
Beyond the preview
Go deeper on 2018-000100-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000100-41.